The combination of Roche’s investigational drug, giredestrant, with Pfizer’s Ibrance didn’t lead to a statistically significant improvement among patients with advanced breast cancer.
About the Author
Discover more from InfoVera USA
Subscribe to get the latest posts sent to your email.
